RCT: Bendamustine plus rituximab vs CHOP plus rituximab as first-line treatment for indolent and mantle-cell lymphomas

Source: Lancet Area: News Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is considered the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma, however there are no randomised comparative study data to show that this regimen is better than other chemotherapy regimens. Bendamustine plus rituximab is effective for relapsed or refractory disease and based on long-standing experience of its use in Germany, this prospective, randomised, open-label non-inferiority study compared this regimen with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas.   Adult patients with newly diagnosed stage III or IV indolent or mantle-cell lymphoma from 81 German oncology centres were randomised to intravenous bendamustine (253 assessed; 90 mg/m2 on days 1 and 2 of a 4-week cycle) or CHOP (253 assessed; cycles every 3 weeks of ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news